Industry Examiner

Gilead’s $7.8B Arcellx buy isn’t just M&A. It’s an “option exercise” on CAR-T: pay up to own the flywheel—manufacturing, label expansion, and the economics of scale.

https://biotech.industryexaminer.com/gilead-arcellx-78b-car-t-option-exercise-anito-cel/

#Biotech #CellTherapy #CART #Oncology #MergersAndAcquisitions #MultipleMyeloma

Gilead’s $7.8B Arcellx buy: when a partnership turns into an “option exercise” in CAR-T - Biotech Industry Examiner

On February 23, 2026, Gilead agreed to acquire Arcellx in a deal valued at up to $7.8 billion—a headline number that’s easy to file under “Big Pharma goes

Biotech Industry Examiner
Feb 25 at 7:10amWeb